The Respimat? Soft Mist? Inhaler represents a unique delivery system for respiratory medications, using an innovative concept with major technological advancements made during prototype development. The Respimat? concept was driven by the intent to solve problems associated with existing inhaler devices for patient use. The following core aims were achieved: (1) avoiding propellants while reducing requirements for patient coordination and inspiratory effort; (2) optimizing drug delivery to the lungs, and; (3) improving the patients’ experience of taking their inhaled medication. The Respimat? inhaler is the first-marketed, pocket-sized inhaler to successfully generate a metered dose of therapeutic aerosol mist from an aqueous solution. Patient feedback has strongly influenced the evolution of the Respimat? inhaler design and instructions for use. The availability of Respimat? augments options for clinicians and patients seeking to choose an inhaler that can effectively and consistently deliver respiratory medication to targeted areas of the lung. In many countries worldwide, Respimat? is available for the administration of tiotropium, olodaterol (and tiotropium/olodaterol in fixed-dose combination), ipratropium/fenoterol, and ipratropium/albuterol. Funding: Boehringer Ingelheim.
展开▼
